RPP: A Key Enzyme in the Protein Kinase C (PKC) Signaling Pathway

Target Name: RPP30

NCBI ID: G10556

RPP30

RPP: A Key Enzyme in the Protein Kinase C (PKC) Signaling Pathway

Ribonuclease P (RPP) is a key enzyme in the protein kinase C (PKC) signaling pathway, which is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The PKC signaling pathway is a highly conserved protein-protein interaction network that is involved in the regulation of numerous cellular processes, including cell growth, differentiation, and inflammation. The RPP enzyme is a key player in this network, as it plays a critical role in the regulation of PKC signaling pathway.

The RPP enzyme is a subunit of the protein ribonuclease P (RPP), which is a 30 kDa protein that is involved in the regulation of DNA-protein interactions. RPP is a single-chain protein that contains 119 amino acid residues and has a calculated pI of 9.95. RPP is highly conserved, with sequence identity of up to 96% between different species, including humans, mice, and bacteria.

RPP is involved in the regulation of several cellular processes, including the PKC signaling pathway, cell adhesion, and cell survival. In the PKC signaling pathway, RPP is involved in the regulation of the activity of the protein kinase CKL, which is a critical enzyme involved in the regulation of PKC activity. CKL is a negative regulator of PKC, and its activity is regulated by RPP. RPP binds to CKL and inhibits its activity, which allows for the activation of PKC and the regulation of cellular processes.

RPP is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. RPP is involved in the regulation of the activity of the protein cadherin, which is a transmembrane protein that is involved in cell-cell adhesion. RPP binds to cadherin and inhibits its activity, which allows for the separation of cells and the formation of tissues.

RPP is also involved in the regulation of cell survival. Cell survival is the process by which cells continue to exist and function. RPP is involved in the regulation of the activity of the protein p53, which is a critical gene that is involved in the regulation of cell survival. RPP binds to p53 and inhibits its activity, which allows for the regulation of cell growth and the inhibition of cell growth beyond what is necessary for survival.

Due to its involvement in several cellular processes, RPP is a potential drug target and biomarker. Many studies have identified potential RPP inhibitors that could be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, one study identified an inhibitor of RPP, called MK-8628, which was shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease.

Another study identified an inhibitor of RPP, called IDR-120, which was shown to be effective in treating various cancers, including breast cancer and lung cancer. IDR-120 is currently being investigated as a potential drug for the treatment of these diseases.

In conclusion, RPP is a key enzyme in the PKC signaling pathway and is involved in the regulation of several cellular processes, including cell adhesion, cell survival, and PKC activity. RPP is highly conserved and has been identified as a potential drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand the role of RPP in cellular processes and to develop effective inhibitors of RPP for the treatment of these diseases.

Protein Name: Ribonuclease P/MRP Subunit P30

Functions: Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5'-ends (PubMed:9037013, PubMed:9630247, PubMed:30454648). Also a component of the MRP ribonuclease complex, which cleaves pre-rRNA sequences (PubMed:28115465)

The "RPP30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPP30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets